Chemed Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.6B+97.3% YoYTTM through 30 Jun 2026
Net Income $275M-8.9% YoYTTM through 30 Jun 2026
Free Cash Flow $323.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 32.5% |
| EBITDA Margin | 16.0% |
| Operating Margin | 13.4% |
| Net Margin | 10.6% |
Returns
30.8%ROE
17.2%ROA
21.2%ROIC
Balance Sheet Health
Debt / Equity0.00x
Current Ratio1.05x
Net Debt-$74.5Mnet cash position
Cash & Equivalents$40.2M
Quality Metrics
Altman Z-Score10.27
Piotroski F-Score6 / 9
FCF Margin12.5%
Rule of 4017.3
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $2.5B
Diluted EPS$19.88TTMFY2025: $18.34
Dividend
$1.20Per share, FY20260.50%Yield-3.0%5-yr growth
Capital Allocation
Capex Intensity2.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| VITAS Healthcare | $1.7B | View detailsVITAS 2026 revenue, prior to Medicare Cap, is estimated to increase 5.5% to 6.5% compared to 2025. | |
| Roto-Rooter | $850.7M | View detailsRoto-Rooter is forecasted to achieve full year 2026 revenue growth of 3.0% to 3.5%. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.